The correct answer is Petechiae and hepatosplenomegaly. This combination reflects the virus's direct impact on the reticuloendothelial system and bone marrow. CMV has a particular predilection for the hepatobiliary epithelium and megakaryocytes, leading to a predictable pattern of organ involvement. The foundational natural history study by Boppana et al. established that in a cohort of 106 neonates with symptomatic cCMV, petechiae and hepatosplenomegaly were each present in 70% or more of patients [3]. This high prevalence makes their co-occurrence a powerful clinical indicator. The underlying pathophysiology involves extramedullary hematopoiesis and direct viral cytopathic effect on the liver and spleen, causing organ enlargement, while concurrent thrombocytopenia—present in a significant majority of these infants—manifests as petechiae. This is not a random pairing but a direct consequence of the systemic viral infection.
Let's analyze why the other options are less specific or not the most indicative primary finding for cCMV in this context. While some components of the other choices can be seen with cCMV, they do not represent the most classic, high-yield combination for initial assessment.
The modern context reinforces this classic presentation. A recent large-scale analysis of NICU newborns in the United States from 2010 to 2020 continues to identify clinical signs like petechiae and hepatosplenomegaly as key triggers for cCMV testing and diagnosis . The persistence of these findings as clinical markers over decades underscores their validity. Furthermore, a review in the Journal of Midwifery & Women's Health emphasizes that the presentation of symptomatic cCMV at birth is often a multisystem disease, with petechiae, jaundice, and hepatosplenomegaly forming the classic triad, a consequence of the virus's hematogenous dissemination to the fetus during maternal primary or non-primary infection . The long-term implications, particularly for sensorineural hearing loss (SNHL), are significant regardless of the initial symptom severity, but the presence of clinically detectable disease at birth, as indicated by findings like petechiae and hepatosplenomegaly, is a strong predictor of more severe neurodevelopmental outcomes .
The most indicative findings for symptomatic congenital CMV are petechiae and hepatosplenomegaly, present in over 70% of cases. This reflects viral targeting of the reticuloendothelial system and bone marrow.
Always evaluate for the full classic triad, which includes microcephaly. Other common signs are thrombocytopenia, jaundice, and sensorineural hearing loss.
Isolated jaundice or poor feeding is nonspecific in neonates. Do not rule out CMV based on the absence of these findings alone, as 90% of infected infants are asymptomatic at birth but remain at risk for late-onset hearing loss.
학습 참고용입니다. 실제 임상은 최신 지침과 소속 기관 프로토콜을 따르세요.